A Case for Pharma In-Licensing
Executive Summary
Examining the internal rate of return for in-licensed compounds versus those developed by a firm's internal R&D, a new study by Mercer Management Consulting shows that while profit margins on in-house drugs are higher, they generate less cash over all due to the cost of capital incurred over long development lead times.